Support for Triple-Negative Breast Cancer Patients After Treatment
A Nurse-Led, Coping and Supportive Care Intervention to Improve Psychosocial Outcomes of Patients with Triple-Negative Breast Cancer During the Transition from Curative Therapy to Surveillance
This project is creating and testing a special program led by nurses to help patients with triple-negative breast cancer manage their feelings and worries after finishing active treatment.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11140472 on NIH RePORTER |
What this research studies
Patients with triple-negative breast cancer often face unique challenges, including a higher risk of recurrence and significant emotional distress once their main treatments are over. During this time, contact with their care team often lessens, leaving many feeling anxious about the future. This program aims to provide tailored support and coping strategies specifically for these patients as they move from active treatment into the surveillance phase. We are developing and refining this nurse-led program, called TRANSITIONS, based on patient and expert feedback, and then testing how well it works in a pilot study.
Who could benefit from this research
Good fit: Ideal candidates are patients with triple-negative breast cancer who are transitioning from curative therapy to the surveillance phase.
Not a fit: Patients who are currently undergoing active treatment for triple-negative breast cancer or those with other types of breast cancer may not directly benefit from this specific program.
Why it matters
Potential benefit: If successful, this program could offer much-needed emotional support and coping tools, helping patients with triple-negative breast cancer feel more secure and less anxious during a vulnerable time.
How similar studies have performed: Currently, there are no specific coping and supportive care programs designed for patients with triple-negative breast cancer during this critical transition period, making this a novel approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Post, Kathryn Elizabeth — Massachusetts General Hospital
- Study coordinator: Post, Kathryn Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.